Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
BMC Cancer ; 23(1): 377, 2023 Apr 25.
Artigo em Inglês | MEDLINE | ID: mdl-37098487

RESUMO

BACKGROUND: Compelling evidence has indicated a significant association between leukocyte mitochondrial DNA copy number (mtDNAcn) and prognosis of several malignancies in a cancer-specific manner. However, whether leukocyte mtDNAcn can predict the clinical outcome of breast cancer (BC) patients has not been well investigated. METHODS: The mtDNA copy number of peripheral blood leukocytes from 661 BC patients was measured using a Multiplex AccuCopy™Kit based on a multiplex fluorescence competitive PCR principle. Kaplan-Meier curves and Cox proportional hazards regression model were applied to investigate the association of mtDNAcn with invasive disease-free survival (iDFS), distant disease-free survival (DDFS), breast cancer special survival (BCSS), and overall survival (OS) of patients. The possible mtDNAcn-environment interactions were also evaluated by the Cox proportional hazard regression models. RESULTS: BC patients with higher leukocyte mtDNA-CN exhibited a significantly worse iDFS than those with lower leukocyte mtDNAcn (5-year iDFS: fully-adjusted model: HR = 1.433[95%CI 1.038-1.978], P = 0.028). Interaction analyses showed that mtDNAcn was significantly associated with hormone receptor status (adjusted p for interaction: 5-year BCSS: 0.028, 5-year OS: 0.022), so further analysis was mainly in the HR subgroup. Multivariate Cox regression analysis demonstrated that mtDNAcn was an independent prognostic factor for both BCSS and OS in HR-positive patients (HR+: 5-year BCSS: adjusted HR (aHR) = 2.340[95% CI 1.163-4.708], P = 0.017 and 5-year OS: aHR = 2.446 [95% CI 1.218-4.913], P = 0.011). CONCLUSIONS: For the first time, our study demonstrated that leukocyte mtDNA copy number might influence the outcome of early-stage breast cancer patients depending on intrinsic tumor subtypes in Chinese women.


Assuntos
Neoplasias da Mama , DNA Mitocondrial , Humanos , Feminino , DNA Mitocondrial/genética , Variações do Número de Cópias de DNA , Neoplasias da Mama/genética , Prognóstico , Leucócitos
2.
Oncotarget ; 9(3): 3677-3689, 2018 Jan 09.
Artigo em Inglês | MEDLINE | ID: mdl-29423075

RESUMO

Hox transcript antisense intergenic RNA (HOTAIR) is a well-known long non-coding RNA (lncRNA) which participates in tumorigenesis and progress of multiple cancers. However, the associations among polymorphisms on HOTAIR, breast cancer (BC) susceptibility and clinical outcomes have remained obscure. In this case-control study, we assessed the interaction between three lncRNA HOTAIR single nucleotide polymorphisms (SNPs) (rs1899663, rs4759314 and rs7958904) on the risk and clinical outcome of breast cancer in a Chinese Han population. In total, 969 breast cancer cases and 970 healthy controls were enrolled in this study. Associations among genotypes, BC risk and survival were evaluated by univariate and multivariate logistic regression to estimate the odds ratio (OR), hazard ratio (HR) and its 95% confidence interval (CI). The disease-free survival (DFS) and overall survival (OS) was calculated by the Kaplan-Meier method. We found that the T allele of rs1899663 and C allele of rs7958904 both achieved significant differences between cases and controls in the single locus analyses (P = 0.017 and 0.010, respectively). Multivariate analyses also revealed the rs1899663 TT genotype and rs7958904 CC genotype were both at higher risk of breast cancer compared with the GG homozygotes (OR = 2.08, 95% CI = 1.20-3.60 and OR = 1.45, 95% CI = 1.01-2.08, respectively). In survival analysis, we observed that the T allele of rs1899663 presented significant differences for both DFS (HR = 1.64, 95% CI = 1.12-2.40) and OS (HR = 2.10, 95% CI = 1.29-3.42) in younger subjects (age ≤ 40). Our findings may provide new insights into the associations among the genetic susceptibility, the fine classifications and the prognosis of breast cancer. Further studies with larger sample size and functional research should also be conducted to validate our findings and better elucidate the underlying biological mechanisms.

3.
Oncotarget ; 9(63): 32108-32118, 2018 Aug 14.
Artigo em Inglês | MEDLINE | ID: mdl-30181802

RESUMO

Triple negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis. In this study, we aimed to conduct a nomogram to predict the survival of individual with TNBC by incorporating significant clinical and laboratory parameters. 404 TNBC patients from the Affiliated Union Hospital of Fujian Medical University between 2006 and 2012 were selected in the training cohort. Cox univariate and multivariate regression analyses were adopted to identify independent prognostic factors. The predictive accuracy and discriminative ability of this nomogram were evaluated by concordance index (C-index) and calibration curve. The accuracy of this nomogram was also compared with the 8th AJCC TNM staging system. An external validation cohort was further performed in an independent cohort of 200 patients between 2012 and 2014. Seven independent prognostic factors, including family history of breast cancer, tumor location, number of positive lymph nodes, histological grade, serum CEA, CA125 and CA153 were identified as independent prognostic factors. A nomogram incorporating these prognostic factors was subsequently conducted and the calibration plot on the probability for 3 or 5 years overall survival (OS) showed an optimal agreement between the nomogram prediction and actual observations. In addition, the C-index of this nomogram was higher than that of TNM staging system in both training and validation cohort (training cohort, 0.76 vs. 0.66, p<0.001 and validation cohort, 0.72 vs. 0.64, p=0.002, respectively). This proposed nomogram could provide more accurate individual prediction for the prognosis of the patients with TNBC and was able to help physicians to identify subgroups of patients at different risk and to decide who need intensive follow-up or additional treatment.

4.
Onco Targets Ther ; 10: 4369-4378, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28919786

RESUMO

The long noncoding RNA (lncRNA) H19 is a maternally expressed imprinted gene that plays important roles in tumorigenesis, progression, and metastasis. However, the association between polymorphisms on H19 and breast cancer (BC) susceptibility has remained obscure. In this case-control study, we assessed the interaction between two lncRNA H19 single-nucleotide polymorphisms (SNPs) (rs217727 C>T, rs2839698 C>T) and the risk of BC in a Chinese Han population. In total, 1,005 BC cases and 1,020 healthy controls were enrolled in this study. Correlations between genotypes and BC risk were evaluated by multivariate logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs). False-positive report probability calculation was also utilized to identify false-positive associations. We observed that the rs217727 T variant was consistently significantly associated with an increased risk of BC in both codominant and dominant models (CT vs CC, OR 1.25, 95% CI 1.03-1.51; TT vs CC, OR 1.56, 95% CI 1.15-2.09; CT + TT vs CC, OR 1.31, 95% CI 1.09-1.57), and all associations remained significant after Bonferroni correction (P<0.025). Subsequent stratified analyses also revealed that associations between BC risk and rs217727 genotypes were more profound in patients with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, and hormone receptor-positive-HER2-negative molecular subtypes (all passed the threshold for Bonferroni correction, P<0.005). These findings extend available data on the association of H19 polymorphisms and BC susceptibility. Based on these results, we encourage further large-scale studies and functional research to confirm our findings and better elucidate the underlying biological mechanisms.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA